Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates.
Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: iwamoto n. Nat Commun. 2023 Mar 23;14(1):1620. doi: 10.1038/s41467-023-37059-x. Nat Commun. 2023. PMID: 36959194 Free PMC article.
A nationwide cross-sectional study using a web-based questionnaire survey of the duration of isolation of COVID-19 inpatients with cancer at Japanese cancer centers.
Itoh N, Akazawa N, Kurai H, Kawamura I, Okinaka K, Fujita T, Sekiya N, Takeda K, Shiotsuka M, Ishikane M, Iwamoto N, Ohmagari N, Suzuki T. Itoh N, et al. Among authors: iwamoto n. J Infect Chemother. 2023 Dec;29(12):1185-1188. doi: 10.1016/j.jiac.2023.08.001. Epub 2023 Aug 2. J Infect Chemother. 2023. PMID: 37541327 Free article.
Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo.
Uraki R, Kiso M, Iwatsuki-Horimoto K, Yamayoshi S, Ito M, Chiba S, Sakai-Tagawa Y, Imai M, Kashima Y, Koga M, Fuwa N, Okumura N, Hojo M, Iwamoto N, Kato H, Nakajima H, Ohmagari N, Yotsuyanagi H, Suzuki Y, Kawaoka Y. Uraki R, et al. Among authors: iwamoto n. Cell Rep. 2023 Dec 26;42(12):113580. doi: 10.1016/j.celrep.2023.113580. Epub 2023 Dec 15. Cell Rep. 2023. PMID: 38103202 Free article.
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma.
Maruki T, Nomoto H, Iwamoto N, Yamamoto K, Kurokawa M, Iwatsuki-Horimoto K, Yamayoshi S, Suzuki Y, Kawaoka Y, Ohmagari N. Maruki T, et al. Among authors: iwamoto n. J Infect Chemother. 2024 Jan 17:S1341-321X(24)00012-6. doi: 10.1016/j.jiac.2024.01.008. Online ahead of print. J Infect Chemother. 2024. PMID: 38242284 Free article.
Surveillance and risk assessment of health screening for vaccine-preventable diseases among international students in Japan: A cross-sectional study in 2020.
Takahata H, Onishi K, Nomoto H, Iwamoto N, Hayashi K, Hori N, Kutsuna S, Kodama EN, Ohmagari N. Takahata H, et al. Among authors: iwamoto n. Hum Vaccin Immunother. 2022 Nov 30;18(6):2136914. doi: 10.1080/21645515.2022.2136914. Epub 2022 Nov 18. Hum Vaccin Immunother. 2022. PMID: 36399767 Free PMC article.
Validation of the severe COVID-19 prognostic value of serum IL-6, IFN-λ3, CCL17, and calprotectin considering the timing of clinical need for prediction.
Yamamoto K, Ohsiro Y, Suzuki T, Suzuki M, Miura S, Nagashima M, Iwamoto N, Takeuchi JS, Kimura M, Sugiura W, Nebuya S, Kurokawa M, Ohmagari N. Yamamoto K, et al. Among authors: iwamoto n. PLoS One. 2023 Mar 30;18(3):e0279897. doi: 10.1371/journal.pone.0279897. eCollection 2023. PLoS One. 2023. PMID: 36996138 Free PMC article.
622 results